Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Brown University
Brown University
University of Pittsburgh
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Washington University School of Medicine
Memorial Sloan Kettering Cancer Center
Rabin Medical Center
Mayo Clinic
National Taiwan University Hospital
Erasmus Medical Center
University of Southampton
Oslo University Hospital
AIO-Studien-gGmbH
AIO-Studien-gGmbH
Shanghai Zhongshan Hospital
Osaka University